Regeneron Pharmaceuticals (REGN) 548.90 $REGN
These 2 Companies Could Revolutionize Heart Disease Prevention
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:21AM CST
Image source: Alnylam Pharmaceuticals via Google Maps. A staggering 600,000 people will die from heart disease in the U.S. alone this year, but if a promising new therapy under development by Alnylam Pharmaceuticals succeeds, then that number...
ALNY: 102.57 (+3.63), MDCO: 40.00 (+1.51), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 56.94 (+3.53), ESRX: 82.99 (-1.47), VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), HZNP: 17.99 (+0.38), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Recovers From Clinton Biotech Beat Down
at Investor's Business Daily - Thu Nov 12, 10:27AM CST
Biotech stocks and drugmakers like Valeant Pharmaceuticals (VRX) took a beating in September when Hillary Clinton accused Big Pharma of price gouging. But Regeneron Pharmaceuticals (REGN) has now bounced back into a buy zone. The New York-based...
VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Joel Marcus, CEO of Alexandria Real Estate Equities, Inc., Receives Lifetime Achievement Award from Biotech Executives
PR Newswire - Thu Nov 12, 7:54AM CST
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA urban innovation cluster locations, announced today that Joel S. Marcus, chairman, chief executive officer and founder, was honored with the NY/NJ CEO Lifetime Achievement Award in recognition of his leadership in the life science community. Mr. Marcus received the award on Wednesday, Nov. 11 during the NY/NJ CEO Conference, hosted by Boston Biotech Conferences, at the Apella(TM) event space at the Alexandria Center® for Life Science - New York City. The award was presented by esteemed past award honorees Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University; Ron Cohen, M.D., president and chief executive officer of Acorda Therapeutics, Inc. and George Yancopoulos, M.D., Ph.D., founding scientist, president and chief scientific officer of Regeneron Pharmaceuticals, Inc.
ARE: 87.49 (-1.26), ACOR: 37.00 (-0.20), REGN: 548.90 (-3.63)
Stock Futures Climb Toward Open; Facebook, LinkedIn, Alphabet Rise
at Investor's Business Daily - Wed Nov 11, 7:52AM CST
Stock futures built on early gains ahead of Wednesday's open. Dow futures were ahead 76.8 points and climbing. Nasdaq 100 futures traded up 23.7 points. S&P 500 futures rose a strong 7.9 points. The stock market today is open, but bond traders are...
BUD: 120.13 (-1.10), CNX: 7.40 (+0.28), FB: 103.95 (-4.07), M: 39.10 (-1.72), ESRX: 82.99 (-1.47), LNKD: 243.00 (-9.96), HZNP: 17.99 (+0.38), JCP: 7.44 (-1.35), GOOGL: 740.07 (-16.46), SNY: 42.99 (-0.65), AAPL: 112.34 (-3.38), REGN: 548.90 (-3.63), CSCO: 26.21 (-1.62)
Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
PR Newswire - Tue Nov 10, 5:01PM CST
Sanofi and Regeneron Pharmaceuticals, Inc. today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent® (alirocumab) Injection 75 mg to their standard-of-care, which included statins. In the 26 percent of patients whose dose was increased to 150 mg, most were able to achieve their pre-specified LDL cholesterol target, with an average additional 14 percent reduction in LDL cholesterol. The results from this and other analyses, which evaluated Praluent every two weeks, were presented at the American Heart Association (AHA) Scientific Sessions in Orlando, FL.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
PR Newswire - Tue Nov 10, 5:00PM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent® (alirocumab) Injection 75 mg to their standard-of-care, which included statins. In the 26 percent of patients whose dose was increased to 150 mg, most were able to achieve their pre-specified LDL cholesterol target, with an average additional 14 percent reduction in LDL cholesterol. The results from this and other analyses, which evaluated Praluent every two weeks, were presented at the American Heart Association (AHA) Scientific Sessions in Orlando, FL.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Why Aegerion Pharmaceuticals Is Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 10, 1:58PM CST
Source: Aegerion Pharmaceuticals What: After reporting third quarter financials and indicating that new competitors were impacting prescription volume trends, shares in Aegerion Pharmaceuticals have tumbled 23% so far today. So what: ...
AMGN: 151.55 (+0.57), AEGR: 10.13 (+0.84), REGN: 548.90 (-3.63)
Avalanche (AAVL) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 1:10PM CST
Avalanche Biotech (AAVL) reported a loss of 55 cents per share in the third-quarter of 2015 on revenues of almost $1 million.
SPPI: 5.24 (+0.17), AAVL: 8.08 (+0.30), CORT: 4.80 (-0.04), REGN: 548.90 (-3.63)
Jim Cramer Sees Priceline as a Buy on the Dip, Also Likes Weyerhaeuser
at The Street - Mon Nov 09, 1:31PM CST
Jim Cramer, TheStreet's portfolio manager of Action Alerts PLUS and host of CNBC's 'Mad Money,' said Monday Priceline's (PCLN) a buy on the dip.
ABX: 7.54 (-0.01), GOLD: 60.08 (+0.14), FCX: 8.68 (-0.09), PCL: 46.19 (-0.34), PCLN: 1,297.75 (-16.26), ATVI: 34.59 (-0.42), AA: 7.99 (+0.17), BHP: 28.41 (+0.22), VALE: 3.97 (+0.04), GLD: 103.56 (-0.29), WY: 29.25 (-0.14), TWTR: 25.18 (-0.95), SNY: 42.99 (-0.65), AAPL: 112.34 (-3.38), REGN: 548.90 (-3.63), GG: 12.01 (+0.18)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
PR Newswire - Sun Nov 08, 6:08AM CST
Sanofi and Regeneron Pharmaceuticals, Inc. today announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor. The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California. The study met both its co-primary endpoints of improvements in signs and symptoms of rheumatoid arthritis (RA) and improvements in physical function, as well as secondary efficacy endpoints.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
PR Newswire - Sun Nov 08, 6:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor. The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California. The study met both its co-primary endpoints of improvements in signs and symptoms of rheumatoid arthritis (RA) and improvements in physical function, as well as secondary efficacy endpoints.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Covered Call Alerts For GoPro, Autodesk, Juno Therapeutics Inc, Regeneron Pharmaceuticals and Synaptics Incorporated Released By InvestorsObserver
PR Newswire - Fri Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GPRO, ADSK, JUNO, REGN and SYNA.
GPRO: 21.16 (-1.99), SYNA: 86.41 (-1.92), JUNO: 50.00 (+0.11), REGN: 548.90 (-3.63), ADSK: 60.45 (-1.30)
This Acronym Really Stinks
at The Street - Thu Nov 05, 10:28AM CST
Don't use it as a gauge of market strength.
NFLX: 103.65 (-5.27), AMZN: 642.35 (-23.25), TSLA: 207.19 (-5.75), SPY: 202.54 (-2.30), FB: 103.95 (-4.07), GOOGL: 740.07 (-16.46), MSFT: 52.84 (-0.48), REGN: 548.90 (-3.63)
New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss
PR Newswire - Thu Nov 05, 7:45AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that a new survey released today at the start of Diabetes Awareness Month found that less than half of recently surveyed U.S. adults with diabetes recognize their risk for vision loss.1 In fact, less than one-fifth (18 percent) of respondents said they were familiar with diabetic macular edema (DME),1 a term that refers to swelling of the macula and is a complication of diabetic retinopathy, the most common diabetic eye disease.2 These findings are part of a survey conducted by the Market Research Group at Everyday Health, Inc. on behalf of Regeneron.
EVDY: 6.25 (-0.45), REGN: 548.90 (-3.63)
Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015
PR Newswire - Thu Nov 05, 7:00AM CST
Praluent is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular morbidity and mortality has not been determined.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Nov 04, 8:29PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2015, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 548.90 (-3.63)
These 2 Companies Could Revolutionize Heart Disease Prevention
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:21AM CST
Image source: Alnylam Pharmaceuticals via Google Maps. A staggering 600,000 people will die from heart disease in the U.S. alone this year, but if a promising new therapy under development by Alnylam Pharmaceuticals succeeds, then that number...
ALNY: 102.57 (+3.63), MDCO: 40.00 (+1.51), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 56.94 (+3.53), ESRX: 82.99 (-1.47), VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), HZNP: 17.99 (+0.38), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Recovers From Clinton Biotech Beat Down
at Investor's Business Daily - Thu Nov 12, 10:27AM CST
Biotech stocks and drugmakers like Valeant Pharmaceuticals (VRX) took a beating in September when Hillary Clinton accused Big Pharma of price gouging. But Regeneron Pharmaceuticals (REGN) has now bounced back into a buy zone. The New York-based...
VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Joel Marcus, CEO of Alexandria Real Estate Equities, Inc., Receives Lifetime Achievement Award from Biotech Executives
PR Newswire - Thu Nov 12, 7:54AM CST
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA urban innovation cluster locations, announced today that Joel S. Marcus, chairman, chief executive officer and founder, was honored with the NY/NJ CEO Lifetime Achievement Award in recognition of his leadership in the life science community. Mr. Marcus received the award on Wednesday, Nov. 11 during the NY/NJ CEO Conference, hosted by Boston Biotech Conferences, at the Apella(TM) event space at the Alexandria Center® for Life Science - New York City. The award was presented by esteemed past award honorees Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University; Ron Cohen, M.D., president and chief executive officer of Acorda Therapeutics, Inc. and George Yancopoulos, M.D., Ph.D., founding scientist, president and chief scientific officer of Regeneron Pharmaceuticals, Inc.
ARE: 87.49 (-1.26), ACOR: 37.00 (-0.20), REGN: 548.90 (-3.63)
Stock Futures Climb Toward Open; Facebook, LinkedIn, Alphabet Rise
at Investor's Business Daily - Wed Nov 11, 7:52AM CST
Stock futures built on early gains ahead of Wednesday's open. Dow futures were ahead 76.8 points and climbing. Nasdaq 100 futures traded up 23.7 points. S&P 500 futures rose a strong 7.9 points. The stock market today is open, but bond traders are...
BUD: 120.13 (-1.10), CNX: 7.40 (+0.28), FB: 103.95 (-4.07), M: 39.10 (-1.72), ESRX: 82.99 (-1.47), LNKD: 243.00 (-9.96), HZNP: 17.99 (+0.38), JCP: 7.44 (-1.35), GOOGL: 740.07 (-16.46), SNY: 42.99 (-0.65), AAPL: 112.34 (-3.38), REGN: 548.90 (-3.63), CSCO: 26.21 (-1.62)
Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
PR Newswire - Tue Nov 10, 5:01PM CST
Sanofi and Regeneron Pharmaceuticals, Inc. today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent® (alirocumab) Injection 75 mg to their standard-of-care, which included statins. In the 26 percent of patients whose dose was increased to 150 mg, most were able to achieve their pre-specified LDL cholesterol target, with an average additional 14 percent reduction in LDL cholesterol. The results from this and other analyses, which evaluated Praluent every two weeks, were presented at the American Heart Association (AHA) Scientific Sessions in Orlando, FL.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
PR Newswire - Tue Nov 10, 5:00PM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent® (alirocumab) Injection 75 mg to their standard-of-care, which included statins. In the 26 percent of patients whose dose was increased to 150 mg, most were able to achieve their pre-specified LDL cholesterol target, with an average additional 14 percent reduction in LDL cholesterol. The results from this and other analyses, which evaluated Praluent every two weeks, were presented at the American Heart Association (AHA) Scientific Sessions in Orlando, FL.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Why Aegerion Pharmaceuticals Is Crashing Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 10, 1:58PM CST
Source: Aegerion Pharmaceuticals What: After reporting third quarter financials and indicating that new competitors were impacting prescription volume trends, shares in Aegerion Pharmaceuticals have tumbled 23% so far today. So what: ...
AMGN: 151.55 (+0.57), AEGR: 10.13 (+0.84), REGN: 548.90 (-3.63)
Avalanche (AAVL) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 1:10PM CST
Avalanche Biotech (AAVL) reported a loss of 55 cents per share in the third-quarter of 2015 on revenues of almost $1 million.
SPPI: 5.24 (+0.17), AAVL: 8.08 (+0.30), CORT: 4.80 (-0.04), REGN: 548.90 (-3.63)
Jim Cramer Sees Priceline as a Buy on the Dip, Also Likes Weyerhaeuser
at The Street - Mon Nov 09, 1:31PM CST
Jim Cramer, TheStreet's portfolio manager of Action Alerts PLUS and host of CNBC's 'Mad Money,' said Monday Priceline's (PCLN) a buy on the dip.
ABX: 7.54 (-0.01), GOLD: 60.08 (+0.14), FCX: 8.68 (-0.09), PCL: 46.19 (-0.34), PCLN: 1,297.75 (-16.26), ATVI: 34.59 (-0.42), AA: 7.99 (+0.17), BHP: 28.41 (+0.22), VALE: 3.97 (+0.04), GLD: 103.56 (-0.29), WY: 29.25 (-0.14), TWTR: 25.18 (-0.95), SNY: 42.99 (-0.65), AAPL: 112.34 (-3.38), REGN: 548.90 (-3.63), GG: 12.01 (+0.18)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
PR Newswire - Sun Nov 08, 6:08AM CST
Sanofi and Regeneron Pharmaceuticals, Inc. today announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor. The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California. The study met both its co-primary endpoints of improvements in signs and symptoms of rheumatoid arthritis (RA) and improvements in physical function, as well as secondary efficacy endpoints.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
PR Newswire - Sun Nov 08, 6:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor. The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California. The study met both its co-primary endpoints of improvements in signs and symptoms of rheumatoid arthritis (RA) and improvements in physical function, as well as secondary efficacy endpoints.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Covered Call Alerts For GoPro, Autodesk, Juno Therapeutics Inc, Regeneron Pharmaceuticals and Synaptics Incorporated Released By InvestorsObserver
PR Newswire - Fri Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GPRO, ADSK, JUNO, REGN and SYNA.
GPRO: 21.16 (-1.99), SYNA: 86.41 (-1.92), JUNO: 50.00 (+0.11), REGN: 548.90 (-3.63), ADSK: 60.45 (-1.30)
This Acronym Really Stinks
at The Street - Thu Nov 05, 10:28AM CST
Don't use it as a gauge of market strength.
NFLX: 103.65 (-5.27), AMZN: 642.35 (-23.25), TSLA: 207.19 (-5.75), SPY: 202.54 (-2.30), FB: 103.95 (-4.07), GOOGL: 740.07 (-16.46), MSFT: 52.84 (-0.48), REGN: 548.90 (-3.63)
New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss
PR Newswire - Thu Nov 05, 7:45AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that a new survey released today at the start of Diabetes Awareness Month found that less than half of recently surveyed U.S. adults with diabetes recognize their risk for vision loss.1 In fact, less than one-fifth (18 percent) of respondents said they were familiar with diabetic macular edema (DME),1 a term that refers to swelling of the macula and is a complication of diabetic retinopathy, the most common diabetic eye disease.2 These findings are part of a survey conducted by the Market Research Group at Everyday Health, Inc. on behalf of Regeneron.
EVDY: 6.25 (-0.45), REGN: 548.90 (-3.63)
Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015
PR Newswire - Thu Nov 05, 7:00AM CST
Praluent is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular morbidity and mortality has not been determined.
SAN: 5.29 (-0.05), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Nov 04, 8:29PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2015, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 548.90 (-3.63)
